Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration

Pharmaceutical Development and Technology

Volumn 19, Issue 4, 2014, Pages 475-485

  Shah, Mansi K ^a   Madan, Parshotam ^a   Lin, Senshang ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Caco 2 cells; Carvedilol; Cellular uptake mechanism; Design of experiments; Oral drug delivery; Solid lipid nanoparticles

Indexed keywords

BEHENIC ACID; CARVEDILOL; GLYCEROL BEHENATE; GLYCEROL STEARATE; MYRISTIC ACID; PALMITIC ACID; POLOXAMER; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRIBEHENIN; TRILAURIN; TRIMYRISIN; TRIPALMITIIN; TRISTEARIN; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUTION; ENTERIC COATED TABLET; FIRST PASS EFFECT; FREEZE DRYING; PARTICLE SIZE; PRIORITY JOURNAL; X RAY DIFFRACTION;

ABSORPTION; ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CARBAZOLES; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; FATTY ACIDS; HUMANS; LIPIDS; LYMPHATIC SYSTEM; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; PROPANOLAMINES; SOLUBILITY; TABLETS;

EID: 84899909546     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.795169     Document Type: Article

References (25)

1. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharma Sci 2006;29: 278-287.
2. Pavankumar B, Karimulla SK. Solid lipid nanoparticles - a brief review. Int J Adv Biopharm 2012;2:35-55.
3. Ku M. Use of the biopharmaceutical classification system in early drug development. The AAPS Journal 2008;10:208-212.
4. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
5. Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 2011;100: 547-557.
6. Bargoni A, Cavalli R, Caputo O, et al. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998;15:745-750.
7. Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16: 751-757.
8. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47: 165-196.
9. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-1405.
10. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-177.
11. Greenhalgh DJ. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci 1999;88:1182-1190.
12. Barton AFM. CRC handbook of solubility parameters and other cohesion parameters. 2nd ed. Boca Raton, FL: CRC Press, 1991.
13. Misra A, Kalariya M, Padhi B, Chougule M. Methotraxate loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation & clinical implications. Drug Del Tech 2004;4:1-12.
14. Lanlan W, Peinan S, Shufang N, Weisan P. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm 2005;31:785-794.
15. Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 1997;157:171-179.
16. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000;89:1073-1084.
17. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Del Rev 2008;60:702-716.
18. Liu CH, Wu CT, Fang JY. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm 2010;36:751-761.
19. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 2007;345:163-171.
20. Yuan H, Miao J, Du YZ, et al. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008;348:137-145.
21. Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210:61-67.
22. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci 2009;36:465-473.
23. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-248.
24. Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008;60:625-637.
25. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008;60:673-691.